{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.85","value":"6.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"description":"The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The EQ-5D VAS records the respondent's self-rated health status on a vertical graduated (0-100) visual analogue scale. Higher EQ-5D VAS scores represent better health status.","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"}],"paramType":"MEAN","populationDescription":"Full analysis set with available data. Patient reported outcomes were only analyzed in adult participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 48","title":"Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}